A Multi-center, Open-label Study Assessing the Safety and Efficacy of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension.
Phase of Trial: Phase III
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Aliskiren (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 07 Nov 2011 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 24 Oct 2007 Status changed from in progress to completed.
- 12 Oct 2006 Status change